- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02105155
Conversion Prograf® to Advagraf® at D7 Versus D90 After Liver Transplantation (Conversion)
Non-inferiority and Tolerance of Conversion From Prograf® to Advagraf® at D7 Versus D90 After Liver Transplantation
Study Overview
Status
Intervention / Treatment
Detailed Description
Rationale :
Conversion from Prograf (tacrolimus administered twice daily) to Advagraf (once-daily prolonged-release tacrolimus) is currently proposed in both stable and de novo liver transplant recipients. However, the early conversion (around D7 after transplantation), during hospitalization, may be difficult due to the more frequent need of dose adjustments under Advagraf than under Prograf, so that there is no consensus on the best period for the conversion. The aim of this prospective, randomized, multicenter trial is to prove the non-inferiority - in terms of efficacy - of the early conversion (at D7) versus the conversion at D90 after liver transplantation.
Primary objective :
To evaluate the incidence of biopsy-proven acute rejection in the 6 first months after liver transplantation, and prove the non-inferiority of the conversion at D7 + / - 3 versus the conversion at D90 + / - 5 (reference group).
Secondary objectives :
Compare the two strategies in terms of:
- Severity of acute rejection (criteres of Banff 97)
- Steroid-resistant acute rejection
- Number of dose adjustments to obtain the target trough level after conversion
- Patient and graft survival Analyse the PK profile of two subgroups (20 patients in each arm) under Advagraf Measure the calcineurin activity in the two groups (in the patients selected for the PK analysis) Evaluate tolerance, with a particular focus on the renal function at 6 months (glomerular filtration rate using MDRD4) and on adverse events.
Primary endpoint:
Percentage of patients with a first episode of biopsy-proven acute rejection.
Methodology :
Multicenter (13 French liver transplant centers), randomized (central randomisation), open study, of non-inferiority, comparing the efficacy at 6 months of two strategies of conversion from Prograf to Advagraf (D7 + / - 3 versus D90 + / - 5), in addition to mycophenolate mofetil and steroids, in liver transplant recipients. If non-inferiority is proved, the two strategies will be compared in terms of superiority. Inclusion of 250 patients (to analyse at least 112 patients in each arm). Calculation of the sample size is based on the following data: Incidence of acute rejection at 6 months = 20% in the 2 groups, Non-inferiority margin = 15%, alpha risk = 2.5%, power = 80%).
Treatments :
- Prograf introduced at 0,1 - 0,2 mg/kg/day
- Mycophenolate mofetil : 1g TD
- Steroids according to the current use in each center Trough blood concentration of tacrolimus will be 8 - 15 ng/mL during the first 3 months, then 5 à 12 ng/mL thereafter.
PK study: For the 40 patients included in the PK study (20 patients per arm), the PK profile (C0, Cmax and AUC) will be established on 9 points : 0 (before Advagraf administration) then at 20min, 40 min, 60 min, 2h, 3h, 4h, 6h, 8h.
- 7 days after conversion in the first group (early conversion)
- 14 + / - 5 days after conversion in the other group (conversion at D90) Calcineurin activity will be assayed on the blood samples used for the trough concentration determination at D5, D7, M1, M3 and M6 and on a baseline sample.
Medicoeconomic study : The costs induced by liver transplantation will be calculated in all the patients included and randomized according to the French recommendations.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75013
- Hôpital Pitié Salpêtrière unité médicale de transplantion hépatique
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria :
- 18 to 75 years
- First liver transplantation
- No contra-indication to tacrolimus, mycophenolate mofetil or steroids
- Informed consent signed
- French Health Assurance
Exclusion Criteria :
- Combined transplantation
- Severe uncontrolled infection
- Hypersensitivity to tacrolimus or its excipients, to other macrolides, to mycophenolate mofetil or its excipients
- Pregnant or lactating woman, or women of childbearing potential without adequate method of contraception
- Cancer or pasthistory of cancer other than basal or squamous cell carcinoma or hepatocellular carcinoma suitable for liver transplantation
- Patients with renal impairment where GFR is less than 30ml/min
- HIV positivity
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Conversion at day 7 ± 3
Conversion from Prograf to Advagraf at D7 ± 3
|
Conversion from Prograf® (tacrolimus administered twice daily) to Advagraf® (once-daily prolonged-release tacrolimus) at day 7±3
|
Active Comparator: Conversion at day 90±5
Conversion from Prograf to Advagraf at 90±5
|
Conversion from Prograf® (tacrolimus administered twice daily) to Advagraf® (once-daily prolonged-release tacrolimus) at day 90±5
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
First episode of acute rejection during the first 6 months
Time Frame: 6 months
|
First episode of acute rejection during the first 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Renal function
Time Frame: 6 months
|
Glomerular filtration rate using MDRD4
|
6 months
|
Adverse effects
Time Frame: 6 months
|
All side effects
|
6 months
|
Severity of acute rejection
Time Frame: 6 months
|
Histological severity of acute rejection using the Banff 2007 criteria
|
6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Yvon Calmus, MD, PhD, Assistance Publique
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P 120907
- HAO 2012 (Other Identifier: University Hospital of Toulouse)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Immunosuppression After Liver Transplantation
-
Technical University of MunichCompleted
-
Klemens BuddeCharite University, Berlin, Germany; DESCARTES Working Group On Transplantation and other collaboratorsUnknownImmunosuppression After Renal Transplantation
-
Red de Terapia CelularUniversidad de Murcia; Hospital Universitario Virgen de la Arrixaca; Public Health... and other collaboratorsCompletedLiver Transplantation | ImmunosuppressionSpain
-
University Hospital, LimogesNot yet recruitingLiver Transplantation | ImmunosuppressionFrance
-
National Institute of Allergy and Infectious Diseases...National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Immune...CompletedLiver Transplantation | Immunosuppression | Liver Transplant RecipientsUnited States, Canada
-
Pontificia Universidad Catolica de ChileUnknownLiver Transplantation | Gene Expression | Immunosuppression ConversionChile
-
University of NebraskaGenzyme, a Sanofi CompanyUnknownLiver Transplantation | Liver Disease | ImmunosuppressionUnited States
-
National Taiwan University HospitalUnknownKidney Transplantation | Immunosuppression | TransplantationTaiwan
-
National Taiwan University HospitalUnknownKidney Transplantation | Immunosuppression | TransplantationTaiwan
-
Yonsei UniversityCompletedPatients With Postoperative Mechanical Ventilation After Liver TransplantationKorea, Republic of
Clinical Trials on Conversion at day 7 ± 3 Prograf® to Advagraf®
-
Hospital Universitari de BellvitgeCompleted
-
Otsuka Pharmaceutical Development & Commercialization...Completed
-
Memorial Sloan Kettering Cancer CenterGlaxoSmithKline; University of WashingtonCompletedProstate Cancer | Castration-resistant, MetastaticUnited States
-
Otsuka Pharmaceutical Development & Commercialization...Completed
-
Duramed ResearchCompletedBone Mineral DensityUnited States
-
Edward KasaraskisCompletedFamilial Amyotrophic Lateral SclerosisUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingBreast Cancer | Atrophic VaginitisUnited States